吸入布地奈德对哮喘性支气管炎患儿预后的临床观察

Observation of therapeutic effect of inhaled budesonide in asthmatic bronchitis

目的:探讨吸入布地奈德对哮喘性支气管炎患儿预后的疗效及影响。方法:对143例具有特异性体质或特异性家族史的哮喘性支气管炎患儿,随机分为观察组71例,对照组72例。住院期间相同治疗,观察组出院后吸入布地奈得气雾剂一年。观察用药后两年内两组病例喘息发作次数、一年的身高增长以及6岁时测得的呼气峰流速(PEF)。结果:观察组吸药期间喘息发作次数均较对照组显著降低(P<0.01),但终止吸药的第二年内,两组的喘息发作次数比较差异无统计学意义;一年内身高增长值及第二年末诊断为哮喘的人数两组比较差异无统计学意义;6岁时测PEF观察组显著大于对照组。结论:吸入布地奈德可减轻气道炎症,减少喘息发作,保护肺功能,但不能改变喘息性疾病的预后。

Objective： To observe the therapeutic effect of inhaled budesonide in children with asthmatic bronchitis. Methods： 143 cases diagnosed as asthmatic bronchitis with other atopie diseases or their parents with atopic diseases were dived into two groups randomly： 71 eases in the observed group and 72 cases in the control group. Both groups received the same treatment during their hospitalization but the observed group received inhaled budesonide for one mare year after the hospitalization, In the following two years, the numbers of wheeze attack, one year＇ s growth in stature and the PEF at age of 6 were counted in two groups. Results： The numbers of wheezing attacks in observed group were obviously fewer than those in the control group （P 〈 0.01） in the first year, then in the next year the two groups showed no significant difference, one year＇ s growth stature and those diagnosed as asthma at the end of the second year showed no significant difference, PEF at age of 6 in observed group was higher than in control group. Conclusions： Inhaled budesenide can reduce airway inflammation and wheezing attack, protect lung function, but can＇ t change natural prognosis of the disease.